News and Updates

Although its exact causes are unknown, researchers have uncovered type 1 diabetes risk factors that increase a person's likelihood of developing the condition.

Check out Breakthrough T1D's ADA 2025 coverage of cutting-edge T1D updates in cures, improving lives, and clinical adoption.

Continuous glucose monitors have been transformative for daily type 1 diabetes management. Can they benefit people without diabetes?

Medical Affairs (+Research and Advocacy) Breakthrough T1D’s Medical Affairs program is bridging the gap between access to and adoption of therapies, treatments, drugs, and devices for T1D. To accomplish this goal, the Medical Affairs team is working on healthcare provider (HCP) education, development of clinical care guidelines, and clinical trial education and awareness. Breakthrough T1D’s […]

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]

Breakthrough T1D is heading to Chicago, IL to attend the 2025 ADA conference from June 20-23 to discuss cutting-edge type 1 diabetes updates.

Breakthrough T1D, Breakthrough T1D Canada, and the Stem Cell Network (SCN) have partnered to support cell therapy research in Canada.

The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.

This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D breakthroughs.